OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared with
 placebo as treatment for major depressive disorder (MDD) in adult females.
Inclusion Criteria:

 -  Moderate to severe major depressive disorder

 Exclusion Criteria:

 -  Prior treatment with botulinum toxin of any serotype for any reason

 -  Use of antidepressant medication for depression within 2 weeks of study

 -  Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis